Stock to Watch: Provectus Biopharmaceuticals, Inc.’s (PVCT)
Provectus Biopharmaceuticals, Inc.’s (PVCT) , a stock from Drug Manufacturers – Major Industry, has a value of $0.02 per share, noted a price change of -0.51% in recent trade close. The lower price P/S ratio indicates attractive the investment. A low P/S can also be effective in valuing growth stocks that have suffered a temporary setback. A low P/S ratio may indicate possible undervaluation, while a ratio that is significantly above the average may suggest overvaluation. Abbreviated as the P/S ratio or PSR, this ratio is also known as a “sales multiple” or “revenue multiple.”
The stock has P/B of 0.45. The price-to-book ratio (P/B Ratio) is a ratio used to compare a stock’s market value to its book value. It is calculated by dividing the current closing price of the stock by the latest quarter’s book value per share. A lower P/B ratio could mean that the stock is undervalued. However, it could also mean that something is fundamentally wrong with the company. As with most ratios, be aware that this varies by industry. This ratio also gives some idea of whether you’re paying too much for what would be left if the company went bankrupt immediately.
Analysts mean Recommendation on a stock is noted at 2.00. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Rating Scale: 1.0 represent “Strong Buy” and 2.0 signify “Buy” 3.0 while shows “Hold”. 4.0 display “Sell” and 5.0 reveal “Strong Sell” rating.
The performance for week is 2.65% and the performance for quarter is at -60.41%. The performance for month is 16.17% and the performance for half year is -92.49%. Its monthly volatility value of 12.78% and volatility for the week is valued at 19.55%. The performance for Year to Date (YTD) is -1.02%.
6.20% shares of the company possessed by Institutional Investors. The net percent change held by Institutional Investors has seen a change of 34.72% in last three month period. Insiders own 5.78% of Provectus Biopharmaceuticals, Inc.’s (PVCT) shares.
The ROA tells us exactly what earnings were generated from the invested capital.
P/E Ratio is for valuing a company that measures its current share price relative to its per-share earnings. The price to earnings ratio indicates the expected price of a share based on its earnings. As a company’s earnings per share being to rise, so does their market value per share. A company with a high P/E ratio usually indicated positive future performance and investors are willing to pay more for this company’s shares. A company with a lower ratio, on the other hand, is usually an indication of poor current and future performance. This could prove to be a poor investment. Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its prescription drug candidates includes PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab.
Latest posts by Eldred Matthew (see all)
- Investors Focused Stock: Sarepta Therapeutics, Inc.’s (SRPT) - February 17, 2017
- Investors Spotlight: Baxter International Inc.’s (BAX) - February 17, 2017
- Investors Reviewing Stock: Clovis Oncology, Inc.’s (CLVS) - February 17, 2017